Inovio Pharma Stock
Inovio Pharma Stock
Our community is currently high on Inovio Pharma with 4 Buy predictions and 2 Sell predictions.
With a target price of 7 € there is potential for a 1215.79% increase which would mean more than doubling the current price of 0.53 € for Inovio Pharma.
Our community identified positive and negative aspects for Inovio Pharma stock for the coming years. 1 users see the criterium "Business model" as a plus for the Inovio Pharma stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Inovio Pharma in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Inovio Pharma vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inovio Pharma | - | - | - | - | - | - | - |
| Ardelyx Inc. | 20.070% | 22.231% | 18.703% | 16.087% | 22.231% | 122.288% | 11.765% |
| Evolus Inc | 0.000% | -13.394% | -17.193% | -52.800% | -13.394% | -35.782% | 53.947% |
| Champions Oncology Inc | -0.910% | -6.034% | 9.000% | 14.496% | -6.034% | 36.250% | -39.444% |
Comments
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $5.00 price target on the stock.
Show more
Ratings data for INO provided by MarketBeat